文献速递肝病消化道肿瘤与早癌

综述:肝细胞癌筛查与影像学诊断的现有方法——当前差距与挑战

Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma-Current gaps and challenges.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-10

本文综述肝细胞癌筛查与影像学诊断的现状,指出指南推荐对慢性乙型肝炎或肝硬化患者进行筛查,但筛查率仍较低且现有筛查手段性能欠佳;超声筛查早期肝细胞癌的灵敏度报告为40%至80%;LI-RADS 2018算法已推进影像诊断标准化;生物标志物评分与简化MRI是改善早期检测的有前景工具。

要点

  • 指南推荐对慢性乙型肝炎或肝硬化患者进行肝细胞癌筛查,但筛查率仍相对较低。
  • 超声筛查早期肝细胞癌的灵敏度报告范围为40%至80%。
  • LI-RADS 2018算法已推进并标准化肝细胞癌的影像学诊断。

核心结论

  • LI-RADS系统已标准化肝细胞癌的影像判读与诊断。
  • 特殊人群的筛查及筛查手段的优化仍有待工作。

研究设计与样本

  • 本综述结合文献检索与专家意见对肝细胞癌筛查与影像诊断领域进行回顾。

主要发现

  • 肝细胞癌发病率与死亡率在世界范围内持续上升。
  • 超声检测早期肝细胞癌的灵敏度报告范围为40%至80%。
  • 基于生物标志物的评分如GALAD及简化MRI等替代影像手段是改善肝细胞癌早期检测的有前景工具。
  • 非酒精性脂肪性肝病(NAFLD)患者及获得持续病毒学应答(SVR)的丙型肝炎(HCV)患者在是否需要肝细胞癌筛查方面存在临床困境。
  • 生物标志物与弹性成像可有助于识别这些人群中肝细胞癌高风险个体。

关键数值与推荐

  • 学会指南推荐对慢性乙型肝炎(CHB)或肝硬化患者进行肝细胞癌筛查。
  • 肝细胞癌筛查采用超声,但其检测早期肝细胞癌的灵敏度报告范围为40%至80%。
  • 影像诊断采用肝脏影像报告和数据系统(LI-RADS 2018版)算法。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality continue to rise worldwide. Society guidelines recommend HCC screening for patients with chronic hepatitis B (CHB) or cirrhosis. Unfortunately, HCC screening rates remain relatively low, and the performance characteristics of current screening modalities are suboptimal. AIM: The aim of the study was to discuss the current state of HCC screening and imaging diagnosis utilising standard and emerging imaging modalities in addition to outlining areas of need and ongoing study. METHODS: A review of the field was performed combining literature searches and expert opinion. RESULTS: The development of the Liver Imaging Reporting and Data System (LI-RADS version 2018) algorithms have advanced and standardised the imaging diagnosis of HCC. While guidelines recommend US for HCC screening, the sensitivity of ultrasound is highly variable for the detection of early-stage HCC with sensitivity reports ranging from 40% to 80%. Biomarker-based scores such as GALAD and alternative imaging modalities such as abbreviated MRI are promising tools to improve HCC early detection. Patients with non-alcoholic fatty liver disease (NAFLD) and patients hepatitis C (HCV) who have achieved sustained virologic response (SVR) can present a clinical dilemma regarding the need for HCC screening. Biomarkers and elastography can aid in identification of individuals at high risk for HCC in these populations. CONCLUSIONS: The LI-RADS system has standardised the imaging interpretation and diagnosis of HCC. Work remains regarding screening in special populations and optimization of screening modalities.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Barnard Giustini A, Ioannou GN, Sirlin C, et al. Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma-Current gaps and challenges. Aliment Pharmacol Ther. 2023. PMID: 37038283. doi:10.1111/apt.17506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。